Table 2.
Association of the expression profile of TYROBP mRNA with clinicopathological factors of low-grade glioma
| Characteristic | Low expression of TYROBP | High expression of TYROBP | p |
|---|---|---|---|
| n | 264 | 264 | |
| WHO grade, n (%) | 0.002 | ||
| G2 | 128 (27.4%) | 96 (20.6%) | |
| G3 | 103 (22.1%) | 140 (30%) | |
| IDH status, n (%) | < 0.001 | ||
| WT | 29 (5.5%) | 68 (13%) | |
| Mut | 233 (44.4%) | 195 (37.1%) | |
| 1p/19q codeletion, n (%) | < 0.001 | ||
| codel | 139 (26.3%) | 32 (6.1%) | |
| non-codel | 125 (23.7%) | 232 (43.9%) | |
| Age, meidan (IQR) | 41 (33, 52.25) | 39 (32, 53) | 0.674 |
| P53 status, n (%) | < 0.001 | ||
| WT | 172 (42.79%) | 101 (25.12%) | |
| Mut | 79 (19.65%) | 150 (37.31%) | |
| ATRX status, n (%) | < 0.001 | ||
| WT | 198 (39.44%) | 135 (26.89%) | |
| Mut | 53 (10.56%) | 116 (23.11%) |